Rakuten Med
San Diego, US · Founded 2010 · 1 known investors
Rakuten Medical is a biotechnology company developing cancer treatments based on its Alluminox platform, an investigational technology built on photoimmunotherapy that combines a drug, device, and related components. It aims to create and commercialize drugs and devices to treat cancers.
Founders & leadership
AB
Abhijit BhatiaExecutive
TP
Tiffany PiecewiczExecutive
SS
Suzane SanExecutive
MG
Miguel Garcia-GuzmanExecutive
MM
Minami MaedaExecutive
TS
Toshiaki SuzukiExecutive
SS
Scott SalkaExecutive
HM
Hiroshi MikitaniNamed on SEC filing
Board
DC
David ChaoBoard director
MD
Mazen DarwazahBoard director
HM
Hiroshi MoriBoard director
EK
Eiichi KagaBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$899.3M disclosed across 16 rounds · 2014–2025
▶$111.5MraisedApr 2026 · 26 investors · BiotechnologyRule 506(b)
▶$111.5MraisedApr 2026 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hiroshi MoriDirector
- Hiroyuki KodamaExecutive Officer
- Hiroshi MikitaniExecutive Officer, Director
- Suzane SanExecutive Officer
- David ChaoDirector
- Toshiaki SuzukiExecutive Officer
- Carlos GarciaExecutive Officer
- Maeda MinamiExecutive Officer
- Abhijit BhatiaExecutive Officer
- Kentaro HyakunoDirector
- Nitin NohriaDirector
- Mazen DarwazahDirector
- Eiichi KagaDirector
- Miguel Garcia-GuzmanDirector
- Tiffany PiecewiczExecutive Officer
- Offering amount
- $116.7M
- Amount sold
- $111.5M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedMay 2025 · 14 investors · BiotechnologyRule 506(b)
▶$1.9MraisedMay 2025 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Abhijit BhatiaExecutive Officer
- Nitin NohriaDirector
- David ChaoDirector
- Tiffany PiecewiczExecutive Officer
- Mazen DarwazahDirector
- Suzane SanExecutive Officer
- Hiroshi MikitaniExecutive Officer, Director
- Hiroshi MoriDirector
- Miguel Garcia-GuzmanDirector
- Eiichi KagaDirector
- Minami MaedaExecutive Officer
- Toshiaki SuzukiExecutive Officer
- Carlos GarciaExecutive Officer
- Kentaro HyakunoDirector
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedMar 2024 · 15 investors · BiotechnologyRule 506(b)
▶$4.2MraisedMar 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ChaoDirector
- Carlos GarciaExecutive Officer
- Mazen DarwazahDirector
- Suzane SanExecutive Officer
- Hiroshi MoriDirector
- Hiroshi MikitaniExecutive Officer, Director
- Kentaro HyakunoDirector
- Hiroshi TakasawaDirector
- Nitin NohriaDirector
- Miguel Garcia-GuzmanDirector
- Takashi ToraishiExecutive Officer, Director
- Abhijit BhatiaExecutive Officer
- Agatha MartindaleExecutive Officer
- Minami MaedaExecutive Officer
- Tiffany PiecewiczExecutive Officer
- Toshiaki SuzukiExecutive Officer
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedOct 2023 · 20 investors · BiotechnologyRule 506(b)
▶$2.2MraisedOct 2023 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kentaro HyakunoDirector
- Mazen DarwazehDirector
- Hiroshi MoriDirector
- Nitin NohriaDirector
- David ChaoDirector
- Toshiaki SuzukiExecutive Officer
- Takashi ToraishiExecutive Officer, Director
- Abhijit BhatiaExecutive Officer
- Tiffany PiecewiczExecutive Officer
- Hiroshi TakasawaDirector
- Hiroshi MikitaniExecutive Officer, Director
- Miguel Garcia-GuzmanDirector
- Carlos GarciaExecutive Officer
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$104.8MraisedSep 2023 · 15 investors · BiotechnologyRule 506(b)
▶$104.8MraisedSep 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tiffany PiecewiczExecutive Officer
- Miguel Garcia-GuzmanDirector
- Nitin NohriaDirector
- David ChaoDirector
- Carlos GarciaExecutive Officer
- Mazen DarwazehDirector
- Takashi ToraishiExecutive Officer, Director
- Kentaro HyakunoDirector
- Hiroshi MikitaniExecutive Officer, Director
- Abhijit BhatiaExecutive Officer
- Hiroshi MoriDirector
- Hiroshi TakasawaDirector
- Offering amount
- $123.7M
- Amount sold
- $104.8M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$70MraisedDec 2022 · 4 investors · BiotechnologyRule 506(b)
▶$70MraisedDec 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miguel Garcia-GuzmanDirector
- Carlos GarciaExecutive Officer
- Tiffany PiecewiczExecutive Officer
- Hiroshi MoriDirector
- David ChaoDirector
- Kentaro HyakunoDirector
- Abhijit BhatiaExecutive Officer
- Takashi ToraishiExecutive Officer, Director
- Nitin NohriaDirector
- Hiroshi MikitaniExecutive Officer, Director
- Hiroshi TakasawaDirector
- Offering amount
- $90M
- Amount sold
- $70M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$166MraisedJul 2021 · 10 investors · BiotechnologyRule 506(b)
▶$166MraisedJul 2021 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miguel Garcia-GuzmanExecutive Officer, Director
- David ChaoDirector
- Takashi ToraishiExecutive Officer, Director
- Kentaro HyakunoDirector
- Ann McGuireExecutive Officer
- Hiroshi MoriDirector
- Carlos GarciaExecutive Officer
- Hiroshi TakasawaDirector
- Nitin NohriaDirector
- Hiroshi MikitaniExecutive Officer, Director
- Offering amount
- $291M
- Amount sold
- $166M
- Sales commissions
- $3M
- Placement agents
- TAP Securities LLC, Momentum Capital Markets, LLC
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Miguel Garcia-GuzmanExecutive Officer, Director
- Takashi ToraishiExecutive Officer, Director
- Hiroshi MikitaniExecutive Officer, Director
- Brenton KeathExecutive Officer
- Carlos GarciaExecutive Officer
- David ChaoDirector
- Kentaro HyakunoDirector
- Hiroshi MoriDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapMD Anderson Cancer Center15 shared keywordsUT MD Anderson is a cancer hospital providing cancer treatment, prevention, clinical care, and research, including new therapies and clinical trials for cancer patients. It is ranked among the top hospitals in the U.S. for cancer care.
Globaldata15 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Bioworld15 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Kura Oncology14 shared keywordsKura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
Companies competing with Rakuten Med for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Rakuten Med do?
- Rakuten Medical is a biotechnology company developing cancer treatments based on its Alluminox platform, an investigational technology built on photoimmunotherapy that combines a drug, device, and related components. It aims to create and commercialize drugs and devices to treat cancers.
- Who are Rakuten Med's investors?
- Rakuten Med's investors include Taiwania Capital.
- How much funding has Rakuten Med raised?
- Rakuten Med has disclosed $899.3M raised across 16 rounds.
- Where is Rakuten Med headquartered?
- Rakuten Med is headquartered in San Diego, US.